准EphA2通路:它可能是骨肉瘤的途径吗?
Giorgia Giordano1,2, Cristina Tucciarello1,3, Alessandra Merlini2
1Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, TO, Italy.
Cell communication and signaling : CCS
|September 9, 2024
概括
铁氨酸激酶受体以林A型受体2 (EphA2) 在骨肉瘤中过度表达,导致瘤进展. 准EphA2为治疗这些侵袭性癌症提供了新的精准医学策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 骨肉瘤是源于介质细胞的侵袭性癌症.
- 目前对晚期,不可切割的骨肉瘤的治疗方法有限.
- 了解分子驱动因素是开发新疗法的关键.
研究的目的:
- 审查以弗林A型受体2 (EphA2) 在骨肉瘤发育和转移中的作用.
- 探索针对骨肉瘤的精密医学中针对EphA2的策略.
- 专注于EphA2在骨髓瘤,软骨瘤和尤文瘤中的相关性.
主要方法:
- 文献综述综合了关于EphA2.2的现有研究.
- 分析与EphA2.2相关的分子,遗传,生物化学和药理学数据.
- 专注于EphA2在瘤进展,转移,自我更新和化学抵抗方面的功能.
主要成果:
- 在骨肉瘤中,EphA2过度表达,并作为一个关键的胎儿蛋白质.
- EphA2信号通路与瘤转移,自我更新和化学抵抗有关.
- 针对治疗或诊断目的的EphA2存在各种方法.
结论:
- 对于骨肉瘤的创新治疗,EphA2 是一个有前途的目标.
- 向EphA2有可能克服当前治疗策略的局限性.
- 对基于EphA2的干预措施进行进一步的研究对于骨髓瘤,软骨瘤和尤文瘤是有必要的.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


